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ABSTRACT
Objective To evaluate tumor vascularity by three-
dimensional power Doppler ultrasound (3D-PDU) in
early and advanced stage primary ovarian cancers and
in metastatic tumors to the ovary.
Patients and methods This was a retrospective analysis
of clinical and sonographic data from 49 women
with primary ovarian cancers or metastatic tumors to
the ovary. All women underwent 3D-PDU prior to
surgery. Vascularization index (VI), flow index (FI) and
vascularization flow index (VFI) from solid portions or
papillary projections in the tumors were calculated using
the Virtual Organ Computer-aided AnaLysis (VOCAL
TM
)
program. Definitive histological diagnosis was obtained
in each case.
Results Among the 49 women, 10 had stage I primary
cancers (five low-malignant potential tumors and five
invasive tumors), 26 had advanced stage primary ovarian
cancers and 13 had metastatic tumors to the ovary. Mean
VI and VFI were significantly higher in advanced stage
tumors and metastatic tumors as compared with early
stage tumors. No differences in 3D-PDU indices were
found between advanced stage and metastatic cancers.
Conclusions Vascular indices derived from 3D-PDU tend
to be higher in advanced stage and metastatic ovarian
cancers as compared with early stage ovarian tumors.
Copyright  2006 ISUOG. Published by John Wiley &
Sons, Ltd.
INTRODUCTION
Angiogenesis plays an essential role in tumor growth and
metastasis1. Several studies using immunohistochemical
techniques have demonstrated that, in ovarian cancer,
angiogenesis may be a prognostic factor2,3. Angiogenesis
may be assessed in vivo using pulsed and color Doppler
ultrasonography, the conventional methods for assess-
ing tumor vascularization. In ovarian tumors Doppler
ultrasound has been used mainly for discriminating
between benign and malignant lesions. Although ini-
tial studies on color and spectral pulsed Doppler were
encouraging4, further studies revealed a wide overlap in
pulsed Doppler indices between malignant and benign
tumors, making this approach impractical from the clin-
ical point of view5. Three-dimensional power Doppler
ultrasound (3D-PDU) is a relatively new technique that
allows tumor vascularization assessment, both quantita-
tively by means of 3D-PDU-derived vascular indices6 and
qualitatively by depicting three-dimensionally the tumor
vascular network7.
Some studies using immunohistochemical staining have
found quantitative differences in angiogenesis in ovarian
cancer according to tumor stage8 and other studies have
shown that Doppler assessment of tumor vascularization
is related to microvessel density in cervical, prostate
and breast cancer9–11. The aim of the present study
was to evaluate whether differences exist in tumor
vascularization as assessed by 3D-PDU in early and
advanced stage primary ovarian cancers and in tumors
that have metastasized to the ovary.
PATIENTS AND METHODS
In this retrospective study data from 49 women diagnosed
as having primary or metastatic ovarian cancer, and who
were evaluated and treated at our institution between
January 2003 and October 2005, were reviewed. A group
of these patients are included in a previous study12.
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The patients’ mean age was 52.9 (range, 17–82) years.
Twenty-eight (57.1%) women were postmenopausal and
21 (42.9%) women were premenopausal. Four women
had bilateral tumors identifiable at ultrasound but only
one tumor per patient was used for analysis in these four
women.
All the women had been evaluated by transvaginal
ultrasound using a Voluson 730 Pro (GE Healthcare, Zipf,
Austria) with a 5–7.5-MHz transvaginal probe and color,
power and pulsed Doppler as well as three-dimensional
(3D) ultrasound capabilities. Transabdominal ultrasound
(3.5–5-MHz) was also performed in the case of large
tumors.
The scanning technique has been described in detail
elsewhere12. Following B-mode evaluation, the two-
dimensional power Doppler gate was activated to assess
tumor vascularization. Power Doppler settings were set
to achieve maximum sensitivity to detect low velocity
flow without artifacts (frequency, 5 MHz; power Doppler
gain, 20 (range, 1–30); dynamic range, 20–40 dB;
edge, 1; persistence, 2; color map, 1; gate, 2; filter,
3; pulse repetition frequency, 0.6 kHz). Central vessel
vascularization was defined as the presence of color
spots within papillary projections, solid areas or the
central part of solid tumors. Power Doppler imaging was
used to identify vessels for subsequent pulsed Doppler
interrogation to obtain a flow velocity waveform and to
confirm the arterial nature of the vessel. Pulsatility index
(PI), resistance index (RI) and peak systolic velocity (PSV,
cm/s) were recorded automatically. The lowest PI and RI
and the highest PSV found in a given tumor, independently
from the vessel in which they were obtained, were used
for analysis. In cases in which no arterial flow was found
(n = 2) pulsed Doppler data were not calculated.
For 3D imaging the volume was activated to obtain a
3D box from either papillary projections, solid areas or,
in the case of mostly solid tumors, the whole tumor. Once
a 3D volume had been obtained, it was stored on a hard
disk in the ultrasound machine. The stored volumes were
further analyzed using the Virtual Organ Computer-aided
AnaLysis (VOCAL) program (Sonoview
TM
, Kretztechnik,
Zipf, Austria). Volume acquisition time lasted from 15 to
20 s depending on the size of the volume box. Using the
VOCAL program, three vascular indices were calculated
from every solid area or papillary projection with color
signals within it, excluding cystic (fluid-filled) areas in
which blood vessels would not be found (Figures 1 and 2).
The three-dimensional volume consists of ‘voxels’
(smallest unit of volume). Voxels contain information
about gray-scale and color according to an intensity scale
ranging from 0 to 100. The vascular indices calculated
were the vascularization index (VI), which is expressed
as a percentage and represents the relative proportion of
power Doppler data within the defined volume; the flow
index (FI), which is the mean signal intensity of this power
Doppler information; and the vascular flow index (VFI),
which is a combination of both6.
Measurements were undertaken using the manual
mode, in plane ‘A’ and a 9◦-rotation step. If there was
Figure 1 (a) Transvaginal ultrasound scan showing a solid cystic
vascularized adnexal mass. (b) Tumor volume estimation using the
Virtual Organ Computer-aided AnaLysis (VOCAL) program. In
this case only the solid portion of the tumor is included in the
analysis. (c) Three-dimensional power Doppler-derived indices
obtained using the VOCAL program. This case was a stage IIIc
serous–papillary adenocarcinoma of the ovary.
more than one non-contiguous solid area, each area was
evaluated separately and the highest VI, FI and VFI
values (which could have been obtained from different
areas) were used for analysis. If the tumor showed areas
Copyright  2006 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2006; 28: 325–329.
Tumor angiogenesis in early, advanced and metastatic ovarian cancer 327
Figure 2 (a) Transvaginal ultrasound scan showing a multilocular
cystic lesion with a solid area arising from internal cyst wall.
(b) Transvaginal two-dimensional power Doppler ultrasound scan
showing color signals within solid area. (c) Solid area volume
estimation using the Virtual Organ Computer-aided AnaLysis
(VOCAL) program.
of low echogenicity, this area was not included in the
VOCAL calculation. All calculations were performed on
the ultrasound machine.
All ultrasound examinations and 3D analyses were
performed by a single operator. Patients were selected
according to availability of the examiner and ultrasound
machine. As this was a retrospective study no Institutional
Review Board approval was sought.
All patients underwent surgery, and a definitive
histological diagnosis was obtained in every case.
Tumors were classified according to the World Health
Organization (WHO) criteria13 and ovarian cancers
were staged according to International Federation of
Gynecology and Obstetrics (FIGO) criteria14.
The Kolmogorov–Smirnov test was used to assess
normal distribution of continuous data. As all continuous
data showed a skewed distribution they were compared
using the Kruskal–Wallis test and the Mann–Whitney
U-test with Bonferroni correction. Categorical variables
were compared using the Chi-square test. P ≤ 0.05 was
considered to be statistically significant. All statistical
analyses were performed using the SPSS 11.0 statistical
package (SPSS Inc, Chicago, IL, USA).
RESULTS
Of the 49 patients, five (10.2%) had tumors of low
malignant potential, 31 (63.3%) had primary invasive
carcinomas and 13 (26.5%) had metastatic tumors to the
ovary (source: colon, six cases; endometrium, two cases;
breast, two cases and liver, mesothelioma and lung one
case each.). Histological diagnoses in primary ovarian
cancers, including low-malignant potential tumors, were
as follows: epithelial cancer 32 cases, sarcoma one
case, immature teratoma one case, limphoma one case,
Sertoli–Leydig tumor one case.
All low-malignant potential tumors and five primary
invasive carcinomas were stage I, so these 10 cases were
grouped as stage I cancers. Twenty-six women with
primary invasive cancers had advanced stage tumors
(three stage II, 18 stage III and five stage IV). Two
women with stage III and two with metastatic cancers had
bilateral tumors. B-mode findings according to tumoral
stage are shown in Table 1. Metastatic tumors were more
frequently solid lesions than were early and advanced
stage primary ovarian cancers (P = 0.009).
Median VI and VFI were significantly higher in
advanced stage tumors as compared with early stage
tumors; they were also significantly higher in metastatic
tumors as compared with early stage tumors. No
differences were found in FI when comparing early
stage cancers with advanced stage and metastatic cancers.
No differences were found between advanced stage and
metastatic cancers in VI, FI and VFI and no differences
were found in RI, PI and PSV among all three groups
(Table 2).
DISCUSSION
Usually tumor angiogenesis is evaluated by assess-
ing microvessel density following immunohistochemical
staining for several endothelial antigens such as CD34,
CD31, factor VIII related antigen and VEGF8,15. Some
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Table 1 B-mode findings according to tumoral stage
Stage
Unilocular solid,
n (%)
Multilocular
solid, n (%) Solid, n (%) Total, n (%)
Early stage, n = 10 4 (40) 5 (50) 1 (10) 10 (100)
Advanced stage, n = 26 5 (19.2) 7 (26.9) 14 (53.8) 26 (100)
Metastatic tumors, n = 13 1 (7.7) 3 (23.1) 9 (69.2) 13 (100)
Table 2 Three-dimensional power-Doppler and pulsed Doppler indices according to stage of ovarian cancer. Data are expressed as median
(interquartile range)
Stage VI VFI FI RI PI PSV (cm/s)
Early stagea, n = 10 9.57 (8.5) 3.06 (3.1) 31.21 (6.1) 0.40 (0.10) 0.59 (0.15) 16.8 (8.5)
Advanced stageb, n = 26 18.02 (10.8) 5.91 (4.1) 33.89 (7.2) 0.45 (0.24) 0.66 (0.45) 14.2 (11.3)
Metastatic tumorsc, n = 13 15.10 (11.5) 5.60 (3.2) 34.79 (6.4) 0.42 (0.15) 0.59 (0.31) 14.0 (10.9)
P a vs. b 0.022 a vs. b 0.005 a vs. b 0.132 a vs. b 0.682 a vs. b 0.501 a vs. b 0.589
a vs. c 0.014 a vs. c 0.032 a vs. c 0.192 a vs. c 0.740 a vs. c 0.740 a vs. c 0.976
b vs. c 0.857 b vs. c 0.814 b vs. c 0.879 b vs. c 0.393 b vs. c 0.195 b vs. c 0.816
FI, flow index; PI, pulsatility index; PSV, peak systolic velocity; RI, resistance index; VFI, vascularization flow index; VI, vascularization
index.
have found that angiogenesis is a prognostic factor both in
early16 and advanced stage ovarian carcinomas17. How-
ever, some researchers have challenged these findings18.
Nonetheless, microvessel density is higher in advanced
stage tumors as compared with early stage ones3,8.
Vascularization can be assessed in vivo by Doppler
ultrasonography. A correlation seems to exist between
the pulsed Doppler indices RI and PI19 or color blood
flow mapping20 and tumor microvessel density. 3D-
PDU, theoretically, provides a more comprehensive
means of assessing tumor vascularization than does two-
dimensional (2D) color or power Doppler by the use of
the vascular indices VI, FI and VFI6 and three-dimensional
depiction of the tumor vascular network7. Some studies
have shown that 3D-PDU may be useful for differentiating
benign from malignant ovarian tumors21–23.
Since microvessel density tends to be higher in advanced
stage ovarian cancers than in early stage tumors, it is
logical to assume that vascular indices derived from 3D-
PDU would be higher in advanced stage ovarian cancers
than in early stage tumors. Apparently, no previous
study has used 3D-PDU to assess tumor vascularization
according to tumoral stage, and only one previous study
has been published that compared PSV (not RI and PI)
according to ovarian cancer stage24. According to that
study PSV did not differ between early and advanced
stage ovarian cancer24. In another study we found no
differences in pulsed Doppler indices between metastatic
and primary ovarian cancer25.
In conclusion, vascularization, as assessed by 3D-
PDU indices, is higher in advanced stage and metastatic
ovarian cancers than in early stage ovarian cancer. These
preliminary results may be of value for future research.
It would be worth exploring whether vascular indices
derived from 3D-PDU in ovarian cancer could be used as
a prognostic factor for this condition.
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